Tiger X Medical Inc Stock Other OTC
Equities
US88677A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 08 | CellProthera and BioCardia, Inc. Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction | CI |
Jun. 10 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2022 | 1.35M | Sales 2023 | 477K | Capitalization | 15.69M |
---|---|---|---|---|---|
Net income 2022 | -11M | Net income 2023 | -11M | EV / Sales 2022 | 26.7 x |
Net cash position 2022 | 5.73M | Net Debt 2023 | 212K | EV / Sales 2023 | 33.3 x |
P/E ratio 2022 |
-3.11
x | P/E ratio 2023 |
-1.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.44% |
Latest transcript on Tiger X Medical Inc
Managers | Title | Age | Since |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
Chief Tech/Sci/R&D Officer | - | 17-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
1st Jan change | Capi. | |
---|---|---|
+20.82% | 127B | |
+21.96% | 116B | |
+24.80% | 27.69B | |
-22.97% | 19.62B | |
-17.01% | 16.26B | |
-19.03% | 15.49B | |
+11.66% | 14.81B | |
-48.41% | 14.39B | |
+54.78% | 14.11B |